Document:

Exhibit
10.10

 

Redactions
with respect to certain portions hereof denoted with “***”

 

AMENDMENT
2 TO THE COLLABORATION AGREEMENT

 

BETWEEN

 

CERTAINTY
THERAPEUTICS, INC.

 

AND

 

H.
LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

 

Moffitt
Agreement Identifier: Anixa-CERTainty Contract (Conejo-Garcia) 17-0173

Project
Title: Development of CAR-T/CER-T Therapies for Ovarian and Prostate Cancer

Moffitt
Principal Investigator: Dr. Jose Conejo-Garcia

 

The
“Agreement” described above was previously entered into on November 17, 2017 (hereinafter “Effective Date) and
duly amended on July 24, 2019 (“Amendment 1 Effective Date”) by and between H. Lee Moffitt Cancer Center and Research
Institute, Inc. a non-profit Florida corporation organized pursuant to Section 1004.43, Florida Statutes, whose address is 12902
Magnolia Drive, Tampa, Florida 33612 (“Moffitt”) and Certainty Therapeutics, Inc., a corporation duly organized under
the laws of Delaware whose address is 3150 Almaden Expressway, Suite 250, San Jose, California 95118 (hereinafter “Company”).
Moffitt and Company are hereinafter referred to individually as “Party” and collectively as “Parties.”

 

WHEREAS,
Moffitt requests an extension of the Agreement end date from November 17, 2020 to November 17, 2021; and

 

WHEREAS,
Moffitt requests Company to provide additional funds to cover Moffitt’s management of services provided by a third-party
vendor to carry out Third Party Materials production as part of the Development Plan; and

 

WHEREAS,
Company agrees to Moffitt’s extended participation in the investigation set forth in the Research Plan attached as Exhibit
B to the original Agreement; and

 

WHEREAS,
Company agrees to provide additional funds to Moffitt as defined herein as Exhibit C-1 in this Amendment 2; and

 

WHEREAS,
Moffitt and Company agree to these modifications as set forth by procedures described in Section 13.9 of the original Agreement.

 

NOW,
THEREFORE, in consideration of the foregoing recitals, which are incorporated herein as covenants, and the mutual promises herein
made and exchanged, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
Company and Moffitt agree to the following:

 

1.
Terms. Capitalized terms in this Amendment 2 shall have the same meaning as those in the Agreement, unless specifically
defined in the Amendment 2. All section and paragraph references refer to sections or paragraphs, as applicable, in the Agreement.

 

    	 

     

    

 

Redactions
with respect to certain portions hereof denoted with “***”

 

2.
Amendments.

 

2.1
ARTICLE 7 Term and Termination shall hereby be deleted and replaced with the following:

 

7.1
This Agreement will commence as of the Effective Date set forth in the first paragraph of this Agreement and unless terminated
otherwise as provided herein, this Agreement will expire forty-eight (48) months from such date, unless extended upon mutual written
agreement of the Parties (“Term”).

 

2.2
Exhibit C-1 as outlined herein shall be incorporated into the Agreement as an addendum to Exhibit C of the Agreement. Exhibit
C-1 describes the additional funding amount to be added to the Budget and the Payment Schedule for said funding amount.

 

3.
Interpretation. Except as expressly modified herein, the Agreement shall remain in full force and effect in accordance
with its terms. To the extent there are any inconsistencies or ambiguities between this Amendment 2 Amendment and the Agreement,
the terms of this Amendment 2 shall supersede the Agreement.

 

IN
WITNESS WHEREOF, the Parties have caused this Amendment 2 to the Agreement to be executed by their duly authorized representatives
as of the date of last signature below (the “Amendment 2 Effective Date”).

 

	CERTAINTY
    THERAPEUTICS, INC.	 
	 	 	 
	BY:	/s/
Amit Kumar	 
	Name:	Amit Kumar	 
	Title:	Chief Executive Officer (CEO)	 
	Date:	October 13, 2020	 

 

	H.
    LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.	 
	 	 	 
	BY:	/s/ Margaret J. Fonner	 
	Name:	Margaret J. Fonner	 
	Title:	Director, Office of Sponsored Research	 
	Date:	10/16/2020	 

 

    	 

     

    

 

Redactions
with respect to certain portions hereof denoted with “***”

 

EXHIBIT
C-1

ADDENDUM
TO BUDGET

 

	Principal Investigator: Conejo-Garcia,
    José 
	BUDGET - YEAR 1

                                                                                 
	 	 	 
	PERSONNEL	 	 	YEAR 1	YEAR
    2	TOTAL
	NAME	ROLE ON PROJECT	Percent Effort Devoted	Calendar Months Devoted	 	Salary
        and Fringe 

        Benefits
	Salary
                                        and Fringe 

        Benefits
	 
	KEY PERSONNEL (MCC A)	 	 	 	 	 	 
	 	 	 	 	 	 	 
	Dr. Conejo-Garcia	PI	***	***	 	 	 	 
	 	 	 	 	 	 	 	 
	Dr. Abate-Daga	Co-I	***	***	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	***	***	 	 	 	 
	TECHNICAL
        STAFF (MCC B)

        
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	SUBTOTALS		 	$       ***	$       -	$       ***
	 	 	 	 	 
	Other Expenses	 	 	 	 	 	 	 
	Subawards/Consortium Contractual Costs	 	 	 	$       ***	 	 
	 	 	 	 	 	 	 
	Alliance Management Fee	 	 	 	$       ***	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	$       ***
	SUBTOTAL DIRECT COSTS	 	 	 	$       ***	$       -	$       ***
	FACILITIES
AND ADMINISTRATIVE COSTS @	***	 	$       ***	#REF!	$       ***
	 	 	 	 	 
	TOTAL COSTS FOR TOTAL PERIOD	 	$      262,804

        
	#REF!	$      262,804

        

	 	 	 	 	 	 
	 	 	 	 	 	$150,000
    upon execution of Agreement
	 PAYMENT
SCHEDULE

        
	 	 	 	 	$112,804
upon completed generation of viral vector for clinical trialExhibit
10.13

 

AMENDMENT
TO COLLABORATION AGREEMENT

  

This
AMENDMENT TO COLLABORATION AGREEMENT (the “Amendment”) is made as of October 19, 2020 (the “Amendment
Effective Date”), by and between Anixa Biosciences, Inc., a Delaware corporation (“Anixa”), and OntoChem
GmbH, a German limited liability company (“OntoChem”). Anixa and OntoChem are referred to herein individually
as a “Party” and collectively as the “Parties.”

 

WHEREAS,
the Parties entered into a Collaboration Agreement (the “Agreement”) on April 14, 2020;

 

WHEREAS,
the Parties agree that more time is necessary to complete the activities set forth in the Research Plan attached as Exhibit A
to the original Agreement; and

 

WHEREAS,
Anixa agrees to provide additional funds to OntoChem to complete the Research Plan.

 

NOW,
THEREFORE, in consideration of the foregoing recitals, and the mutual promises herein made and exchanged, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree to the following:

 

1.
Terms. Capitalized terms in this Amendment shall have the same meaning as those in the Agreement, unless specifically defined
in this Amendment.

 

2.
Amendments.

 

2.1
Section 3.1(a) of the Agreement is hereby amended and restated to read in its entirety as follows:

 

3.1(a)
pay OntoChem: (i) 16,667 Euros withing five (5) days after the Effective Date; (ii) five (5) installments in the amount of 16,667
Euros on each one-month anniversary of the Effective Date, except that the last such payment will be due on October 21, 2020;
and (iii) three (3) installments in the amount of 8,334 Euros on each one-month anniversary of the Effective Date commencing on
November 14, 2020; and

 

2.2
Section 3.1(b) of the Agreement is hereby amended and restated to read in its entirety as follows:

 

3.1(b)
reimburse OntoChem for its out-of-pocket expenses incurred in performing the Research Plan on a pass-through basis without mark-up,
within thirty (30) days after delivery of an invoice therefor (including reasonable supporting documentation), provided that Anixa
has approved such expenses in advance and in writing (including in regard to the selection of specific Hit Compounds to be synthesized
and analyzed in biological assays). It is estimated that OntoChem’s out-of-pocket expenses under the Research Plan will
include 165,000 Euros payable to Tube Pharmaceuticals GmbH as a subcontractor of OntoChem, subject to Section 2.5.

 

    	-1-

     

    

 

2.3
Section 4.6 of the Agreement is hereby amended and restated to read in its entirety as follows:

 

4.6
Survival. Expiration or termination of this Agreement will not affect the rights and obligations of the Parties that accrued
prior to the effective date of such expiration or termination. The following provisions will remain in effect following expiration
or termination of this Agreement and the Parties will continue to be bound thereby: Sections 2.4, 2.7, 2.8 (last sentence only),
3.2, 3.3, 3.4, 3.5, 4.5, 4.6, 5, 6, 8 and 9.

 

2.
Interpretation. Except as expressly modified herein, the Agreement shall remain in full force and effect in accordance
with its terms. To the extent there are any inconsistencies or ambiguities between this Amendment and the Agreement, the terms
of this Amendment shall supersede the Agreement.

 

3.
Governing Law. This Amendment and the rights and obligations of the Parties hereunder will be governed by the laws of the
State of Delaware without regard to the conflict of laws provisions of any jurisdiction. The Parties agree that the 1980 United
Nations Convention on Contracts for the International Sale of Goods shall not apply to this Amendment.

 

4.
Counterparts. The Parties may execute this Amendment in multiple counterparts, all of which together will constitute one
instrument. Signatures to this Amendment delivered by facsimile or other electronic transmission (e.g., portable document format
(PDF)) will be deemed to be binding as original signatures.

 

IN
WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.

 

 

	ANIXA
    BIOSCIENCES, INC.	 	ONTOCHEM
    GMBH
	 	 	 	 	 
	By:	/s/
    Amit Kumar	 	By:	/s/
    Lutz Weber
	 	Amit
    Kumar, Ph.D.	 	 	Lutz
    Weber, Ph.D.
	 	President
    and CEO	 	 	CEO

 

    	-2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]